TY - JOUR
T1 - Role of β-lactamase in the susceptibility of clinical isolates to β-lactam antibiotics
AU - Kusumo, Amin Subandrio W.
AU - Sri-Budayanti, N. N.
AU - Widayati, A.
AU - Wiwing, V.
AU - Nusatya, M. A.C.M.
N1 - Publisher Copyright:
© 2004, Faculty of Medicine, Universitas Indonesia. All rights reserved.
PY - 2004/7/1
Y1 - 2004/7/1
N2 - Combination of β-lactam antibiotic with β-lactamase inhibitor has been proven to overcome resistance caused by β-lactamase production. An evaluation to the MIC of some β-lactam antibiotics to b-lactamase producing isolates will be reported. A.anitratus, E.coli, K.pneumoniae, Proteus sp, Pseudomonas sp, S.aureus, S.epidermidis, S.pneumoniae, S.viridans, and β-hemolytic Streptococcus, were challenged to Ampicillin/Sulbactam (AMS), Amoxicillin/Clavulanic acid (AMC), Cefoperazone (CFP), Cefoperazone/ Sulbactam (CSL), Ceftriaxone (CRO), dan Cefotaxime (CTX) using ETest techniques. β-lactamase production was identified using Cefinase disk. Sixtyfour percent of isolates were capable of producing β-lactamase. All E.coli and K.pneumoniae tested were β-lactamase producer, none of Proteus sp, Pseudomonas sp, and S.epidermidis tested produced β-lactamase. In β-lactamase producing group, Sulbactam was able to reduce resistance to CFP from 25% to 5%. About 20% of β-lactamase producing isolates which were resistant to CFP, were susceptible to CSL. Susceptibility of S.viridans to AMS, AMC, CFP, and CSL was higher than 80%, but less than 50% to CRO and CTX. S.pneumoniae was less susceptible to tested antibiotics, 50 to 60% susceptibility was shown to AMC, CFP, and CSL. S.aureus was 60 to 70% susceptible, while β-haemolytic Streptococcus showed good response to the tested antibiotics. Only 30% or less of K.pneumoniae and E.coli was susceptible to AMS and AMC. A.anitratus showed good susceptibility only to AMS (78%) and CSL (89%). Sixtyfour percent of isolate studied produced β-lactamase. β-lactamase inhibitor could reduce resistance of β-lactamase producing organism to β-lactam antibiotic from 25 to 5 percent.
AB - Combination of β-lactam antibiotic with β-lactamase inhibitor has been proven to overcome resistance caused by β-lactamase production. An evaluation to the MIC of some β-lactam antibiotics to b-lactamase producing isolates will be reported. A.anitratus, E.coli, K.pneumoniae, Proteus sp, Pseudomonas sp, S.aureus, S.epidermidis, S.pneumoniae, S.viridans, and β-hemolytic Streptococcus, were challenged to Ampicillin/Sulbactam (AMS), Amoxicillin/Clavulanic acid (AMC), Cefoperazone (CFP), Cefoperazone/ Sulbactam (CSL), Ceftriaxone (CRO), dan Cefotaxime (CTX) using ETest techniques. β-lactamase production was identified using Cefinase disk. Sixtyfour percent of isolates were capable of producing β-lactamase. All E.coli and K.pneumoniae tested were β-lactamase producer, none of Proteus sp, Pseudomonas sp, and S.epidermidis tested produced β-lactamase. In β-lactamase producing group, Sulbactam was able to reduce resistance to CFP from 25% to 5%. About 20% of β-lactamase producing isolates which were resistant to CFP, were susceptible to CSL. Susceptibility of S.viridans to AMS, AMC, CFP, and CSL was higher than 80%, but less than 50% to CRO and CTX. S.pneumoniae was less susceptible to tested antibiotics, 50 to 60% susceptibility was shown to AMC, CFP, and CSL. S.aureus was 60 to 70% susceptible, while β-haemolytic Streptococcus showed good response to the tested antibiotics. Only 30% or less of K.pneumoniae and E.coli was susceptible to AMS and AMC. A.anitratus showed good susceptibility only to AMS (78%) and CSL (89%). Sixtyfour percent of isolate studied produced β-lactamase. β-lactamase inhibitor could reduce resistance of β-lactamase producing organism to β-lactam antibiotic from 25 to 5 percent.
KW - Antibiotic susceptibility
KW - MIC
KW - β-lactam antibiotic
KW - β-lactamase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85008879602&partnerID=8YFLogxK
U2 - 10.13181/mji.v13i3.147
DO - 10.13181/mji.v13i3.147
M3 - Article
AN - SCOPUS:85008879602
VL - 13
SP - 140
EP - 145
JO - Medical Journal of Indonesia
JF - Medical Journal of Indonesia
SN - 0853-1773
IS - 3
ER -